Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Group Plc LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 34.00 33.10 34.90 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27.9 -2.1 1.0 34.0 143

Circassia Group Plc Proposed Change of Name and Notice of GM

11/08/2022 7:00am

UK Regulatory (RNS & others)

Circassia (LSE:CIR)
Historical Stock Chart

From Jun 2022 to Dec 2022

Click Here for more Circassia Charts.


RNS Number : 6284V

Circassia Group Plc

11 August 2022

Circassia Group PLC

("Circassia" or the "Company")

Proposed Change of Name


Notice of General Meeting

Circassia Group PLC, (AIM: CIR), a company engaged in the design, development and commercialisation of medical devices for asthma diagnosis and management, announces that the Company intends to change its name to Niox Group plc.

The directors believe that the change of name will more closely align its corporate identity and growth strategy with the identity of its principal market leading product, NIOX VERO.

The proposed change of name, in order to take effect, requires shareholders to pass a special resolution at a general meeting of the Company. A circular was sent to shareholders on 10 August 2022 to convene a general meeting of shareholders on 1 September 2022 (the "General Meeting") in order for them to vote on the Company's proposed change of name. The General Meeting will be held at 10.00 a.m. on 1 September 2022 at the Company's registered office: Hayakawa Building, Edmund Halley Road, Oxford Science Park, Oxford, OX4 4GB.The TIDM 'NIOX' has been reserved.

Full details on the implementation of the change of name, including any changes to the Group's website, and the effective date for the change of name and the TIDM will be announced after the General Meeting.



Ian Johnson, Executive Chairman Tel: +44 (0) 1865 405 560

Michael Roller, Chief Financial Officer

Singer Capital Markets (Nominated Adviser and Broker)

Aubrey Powell/ Jen Boorer Tel: +44 (0) 20 7496 3000

About Circassia

Our ambition is to improve the quality of life of millions of people suffering from asthma. The company is engaged in the design, development and commercialisation of medical devices for the diagnosis and management of asthma. Today our device, NIOX VERO, is used by healthcare professionals and leading research organisations. We passionately believe in empowering everyone to manage their health at home and are developing NIOX for home use to meet this need. At present, Circassia provides products and services in around 50 countries. For more information please visit .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

August 11, 2022 02:00 ET (06:00 GMT)

1 Year Circassia Chart

1 Year Circassia Chart

1 Month Circassia Chart

1 Month Circassia Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221208 11:07:12